Recent Updates
Recently added Catalysts

Advanced EGFR Mutant Non-Small Cell Lung Cancer: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$794Muniverse median $1.20B
Allocated capital$794M$794M competing
Phase 3 or filed00 mid, 1 early
Pure plays1this indication only
Capital rank163/299crowding rank 174

Advanced EGFR Mutant Non-Small Cell Lung Cancer is uncontested. Nuvectis Pharma (NVCT) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with NXP900 in phase 1.

There is no public comparable to price it against, and NVCT runs clinical programmes in this indication and nothing else, so its $794M market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$794M of allocated capital sits in Advanced EGFR Mutant Non-Small Cell Lung Cancer, ranking it 163rd of 299 indications by the money committed to it.

Companies developing drugs for Advanced EGFR Mutant Non-Small Cell Lung Cancer 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
NVCTNuvectis PharmaNXP900Phase 11$794MYes1 23 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Advanced EGFR Mutant Non-Small Cell Lung Cancer counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Advanced EGFR Mutant Non-Small Cell Lung Cancer has one competitor and a median of $794M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Glioma1 company · $792M · median $2.4BUncontestedCancer Pain1 company · $798M · median $4.0BUncontestedMetastatic Head and Neck Squamous Cell Carcinoma1 company · $772M · median $1.5BUncontestedPancreatic Ductal Adenocarcinoma1 company · $768M · median $3.8BUncontestedAdvanced Gastroesophageal Adenocarcinoma1 company · $767M · median $3.8BUncontestedDiffuse Large B-Cell Lymphoma3 companies · $834M · median $351MOrphan cornerCervical Cancer1 company · $848M · median $2.5BUncontestedNon-Muscle Invasive Bladder Cancer (NMIBC)1 company · $723M · median $8.7BUncontested

Advanced EGFR Mutant Non-Small Cell Lung Cancer pipeline questions

Which biotech companies are developing drugs for Advanced EGFR Mutant Non-Small Cell Lung Cancer?

Nuvectis Pharma (NVCT, NXP900, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Advanced EGFR Mutant Non-Small Cell Lung Cancer.

How advanced is the Advanced EGFR Mutant Non-Small Cell Lung Cancer pipeline?

Of the 1 clinical-stage programme in Advanced EGFR Mutant Non-Small Cell Lung Cancer, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Advanced EGFR Mutant Non-Small Cell Lung Cancer?

No. NVCT is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Advanced EGFR Mutant Non-Small Cell Lung Cancer, which is why the indication is classified as uncontested.

When is the next Advanced EGFR Mutant Non-Small Cell Lung Cancer catalyst?

The next dated catalyst in Advanced EGFR Mutant Non-Small Cell Lung Cancer is NVCT on 23 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map